AMAG Pharmaceuticals, Inc. (AMAG) Scheduled to Post Quarterly Earnings on Wednesday
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is scheduled to issue its quarterly earnings data before the market opens on Wednesday, November 1st. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.18. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm had revenue of $158.39 million for the quarter, compared to the consensus estimate of $158.83 million. During the same quarter in the prior year, the business earned $1.45 EPS. The business’s revenue for the quarter was up 24.3% compared to the same quarter last year. On average, analysts expect AMAG Pharmaceuticals to post $-1.5 EPS for the current fiscal year and $-3.07 EPS for the next fiscal year.
AMAG Pharmaceuticals, Inc. (NASDAQ AMAG) opened at 15.55 on Wednesday. The firm’s 50-day moving average price is $18.27 and its 200 day moving average price is $18.90. AMAG Pharmaceuticals, Inc. has a 12-month low of $15.20 and a 12-month high of $36.83. The firm’s market cap is $548.73 million.
AMAG has been the topic of a number of recent research reports. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Wednesday, October 4th. BidaskClub upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, July 24th. Deutsche Bank AG set a $24.00 price target on shares of AMAG Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, July 7th. Finally, Citigroup Inc. cut their price target on shares of AMAG Pharmaceuticals to $24.00 and set a “hold” rating on the stock in a report on Friday, July 7th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $26.92.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.